Ex­elix­is shells out $100M cash in a pair of deals, shoot­ing for dif­fer­ent takes on CD47, AD­Cs

Now that its cabozan­ti­nib fran­chise — in­clud­ing Cabome­tyx tablets and Cometriq cap­sules — has nes­tled its way in­to block­buster sta­tus, Ex­elix­is is re­plen­ish­ing the pipeline with some ear­ly-stage bets.

The biotech re­vealed a pair of deals right as it re­port­ed Q3 re­sults, shelling out a to­tal of $100 mil­lion in cash to grab a pre­clin­i­cal an­ti­body tar­get­ing SIR­Pα and a Phase I pep­tide-drug con­ju­gate. There are al­so plen­ty of biobucks at­tached should the com­pounds make it down the treach­er­ous de­vel­op­ment jour­ney.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER